tev vcp n terminal (Sangon Biotech)
86
Structured Review
Sangon Biotech
tev vcp n terminal
Tev Vcp N Terminal, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tev+vcp+n+terminal/his+n+terminal+tev+vcp/pm42060985-215-3-8
Average 86 stars, based on 1 article reviews
Tev Vcp N Terminal, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tev+vcp+n+terminal/his+n+terminal+tev+vcp/pm42060985-215-3-8
Average 86 stars, based on 1 article reviews
tev vcp n terminal - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
Plasmid Preparation:Article Title: ATI-1 mediated disruption of the VCP-UFL1-Beclin1 axis thwarts autophagy initiation to trigger metabolic catastrophe in autophagy-addicted cancers. Article Snippet: Targeting autophagy initiation represents a promising strategy to disrupt the metabolic resilience of cancer cells.. In this study, we identified ATI-1 as a novel small-molecule inhibitor that selectively blocks the early stages of autophagosome formation.. Importantly, we discovered that ATI-1-mediated de novo inhibition of autophagy initiation leads to a synergistic surge in cell death under nutrient-deprived conditions, revealing a critical, context-specific vulnerability in autophagy-dependent malignancies. Synthesized:Article Title: ATI-1 mediated disruption of the VCP-UFL1-Beclin1 axis thwarts autophagy initiation to trigger metabolic catastrophe in autophagy-addicted cancers. Article Snippet: Targeting autophagy initiation represents a promising strategy to disrupt the metabolic resilience of cancer cells.. In this study, we identified ATI-1 as a novel small-molecule inhibitor that selectively blocks the early stages of autophagosome formation.. Importantly, we discovered that ATI-1-mediated de novo inhibition of autophagy initiation leads to a synergistic surge in cell death under nutrient-deprived conditions, revealing a critical, context-specific vulnerability in autophagy-dependent malignancies. |